ORG
Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy
MTLE, Epilepsy, Cell Therapy, RMAT, Identifier, drug-resistant
FDA okays Novartis’ second IgA nephropathy therapy Vanrafia
Vanrafia, United States Food and Drug Administration, Approved, Novartis, IGA Glomerulonephritis, Proteinuria
Roche plans Phase 3 for its latest Alzheimers drug attempt after unveiling more early data
Title Roche Advances Alzheimer’s Re Sources:
Cellares’ cell therapy factory-in-a-box scores coveted advanced manufacturing technology tag from FDA
Cell Therapy, Advanced Manufacturing Technology, United States Food and Drug Administration, Technology, Identifier, Cell Shuttle, production, Cellares, Biologics License Application, Investigational New Drugs
Sanofi adds new inflammatory target to growing Nurix tie-up
Nurix, sanofi, Target, STAT6 protein, human, cellular targeting, Collaboration, Inflammation, Autoimmune Diseases, TRANSCRIPTION FACTOR, DEL-AI
Atsena reels in $150M to advance work on ocular gene therapies
Atsena, Retinoschisis, Juvenile, X-Linked, United States Food and Drug Administration, Dependovirus, Cloning Vectors, Hereditary, Retinal Diseases, Blindness, ATSN-201, ATSN-101
Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships
Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game
Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed
Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome
Mass Firings at FDA Spark Concerns Over Agency’s Future
FDA, layoffs, leadership changes, public health, drug regulation, Trump administration
AIRNA nets $155M series B to launch clinical test of RNA editing tech
RNA Editing, Airna, AIR-001, RNA